通用名称和剂型：
厄贝沙坦，氢150mg/12.5mg ， 300mg/12.5mg选项卡。
公司名称：
赛诺菲 - 安万特
主治AVALIDE ：
高血压。
成人剂量为AVALIDE ：
以每日一次。控制单药治疗：最初150/12.5mg ，滴定然后300/25mg如果需要300/12.5mg的。替代治疗：可被取代用于滴定的组件。初始治疗：开始1-2周150/12.5mg ，然后滴定，需要最大300mg/25mg 。最大的影响在2-4周内服药后的变化。严重肾功能不全（肌酐清除率≤ 30ml/min的） ：不建议。
儿童的剂量AVALIDE ：
不推荐使用。
药理类别：
血管紧张素Ⅱ受体阻滞剂+利尿剂。
禁忌症：
无尿。磺胺类药物过敏。糖尿病患者同时阿利吉仑。
警告/注意事项：
胎儿毒性可能发展;如果终止妊娠检测。血管内血容量减少，不使用作为初始治疗。低血容量。肝功能损害。严重瑞士法郎。严重的肾脏疾病。肾动脉狭窄。哮喘。 Postsympathectomy 。 SLE 。痛风。急性近视。继发闭角型青光眼。监测电解质。老年人。新生儿。怀孕（Cat.D）显示器。哺乳母亲：不推荐。
相互作用：
见禁忌。与ARBs的双重抑制肾素-血管紧张素系统， ACE抑制剂，或阿利吉仑可能会增加低血压，高血钾，肾功能变化的风险;密切监察。伴随阿利吉仑肾功能不全（肌酐清除率<60mL/min）：不建议。高钾血症与K+补充剂， K+利尿剂，K+含食盐代用品。体位性低血压，酒精，其他中枢神经系统抑制剂。低钾血症，糖皮质激素，促肾上腺皮质激素。加强其他抗高血压药，筒箭毒碱。可能是拮抗的非甾体抗炎药，包括COX-2抑制剂。拮抗去甲肾上腺素。调整antihyperglycemics 。减少吸收消胆胺，考来替泊树脂。可能会增加锂中毒。低钠血症的风险与卡马西平（显示器） 。会干扰甲状旁腺测试。
不良反应：
头晕，乏力，肌肉疼痛，胃肠不适，感冒，胸部疼痛，电解质紊乱，高血糖，高尿酸血症，低镁血症，光敏性，体位性低血压，胆固醇和甘油三酯水平增加，视力障碍，横纹肌溶解症（罕见） 。
如何提供：
标签- 30 ，90
Avalide-包装规格：
AVALIDE TAB 30012.5MG 90
(IRBESARTANHYDROCHLOROTHIAZIDE)
AVALIDE TAB 30012.5MG 30
(IRBESARTANHYDROCHLOROTHIAZIDE)
AVALIDE TAB 15012.5MG 90
(IRBESARTANHYDROCHLOROTHIAZIDE)
AVALIDE TAB 15012.5MG 30
(IRBESARTANHYDROCHLOROTHIAZIDE)

Generic Name and Formulations:
Irbesartan, hydrochlorothiazide; 150mg/12.5mg, 300mg/12.5mg; tabs.
Company:
Sanofi Aventis
Indications for AVALIDE :
Hypertension.
Adult Dose for AVALIDE :
Take once daily. Not controlled on monotherapy: initially 150/12.5mg, titrate to 300/12.5mg then 300/25mg if needed. Replacement therapy: may be substituted for titrated components. Initial therapy: start at 150/12.5mg for 1–2 weeks, then titrate as needed up to max 300mg/25mg. Maximum effects within 2–4 weeks after dose change. Severe renal impairment (CrCl ≤30mL/min): not recommended.
Children's Dose for AVALIDE :
Not recommended.
Pharmacological Class:
Angiotensin II receptor blocker + diuretic.
Contraindications:
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Intravascular volume depletion; do not use as initial therapy. Hypovolemia. Hepatic impairment. Severe CHF. Severe renal disease. Renal artery stenosis. Asthma. Postsympathectomy. SLE. Gout. Acute myopia. Secondary angle-closure glaucoma. Monitor electrolytes. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Interactions:
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Orthostatic hypotension with alcohol, other CNS depressants. Hypokalemia with corticosteroids, ACTH. Potentiates other antihypertensives, tubocurarine. May be antagonized by NSAIDs, including COX-2 inhibitors. Antagonizes norepinephrine. Adjust antihyperglycemics. Reduced absorption with cholestyramine, colestipol resins. May increase lithium toxicity. Risk of hyponatremia with carbamazepine (monitor). May interfere with parathyroid tests.
Adverse Reactions:
Dizziness, fatigue, musculoskeletal pain, GI upset, influenza, chest pain, electrolyte disorders, hyperglycemia, hyperuricemia, hypomagnesemia, photosensitivity, orthostatic hypotension, increased cholesterol and triglyceride levels, visual disturbances, rhabdomyolysis (rare).
How Supplied:
Tabs—30, 90